Latest Comments on EP Vantage's Articles

1. E Nuff Sed on Sanofi-Aventis Going OTC with Chattem Buy: Don't know where you got the sales data from but it is way off. ... more »
2. E Nuff Sed on Sanofi-Aventis Going OTC with Chattem Buy: Smart move. The market is paying much higher P/E multiples for... more »
3. Furd Turgeson on Facet Rebuffs Biogen: Will a White Knight Emerge?: Good balanced look at FACT. While it seems that Biogen did try to... more »
4. sierranvin on High Hopes Remain for Celgene's Revlimid: yeah, like your one patient anecdote adds something to a... more »
5. daphne doesn't believe on High Hopes Remain for Celgene's Revlimid: yeah, my sister ended up in the emergency room in february with a... more »
6. Vobogeck on Merck KGaA: Another Stumble Leaves Investors Worried: Merck KGaA, which trades on the DAX, is an unrelated entity to... more »
7. Pierr Johnson on Genzyme's Very Bad Year: Kudos for the insights. Still, it is important to point out the... more »
8. frosty on Genzyme's Very Bad Year: Mr. Icahn is interested only in turning a fast buck. People like... more »
9. San Juan on Genzyme's Very Bad Year: The article highlights all the known information that has produced... more »
10. Justin M. Hall on Genzyme's Very Bad Year: Regarding Icahn, check out Biogen Idec (BIIB) mid-2007. As I... more »
11. stockinvestor on Genzyme's Very Bad Year: I agree with the facts that you provide in your article, but I... more »
12. InvestmentGuru on Poniard Pharmaceuticals' Gamble Doesn't Pay Off: CEO JM is a gambler and should be put behind bars for not... more »
13. Justin M. Hall on NeurogesX: Next Stop, U.S. Market: EP: Thank you for the heads up on NGSX. Justin more »
14. jay brebner on Poniard Pharmaceuticals' Gamble Doesn't Pay Off: spear was a very risky trial given the way it was designed. their... more »
15. northernerx on Direction of Cholesterol Debate Could Benefit Abbott Labs: There are (at least) two components of HDL. Niaspan raises levels... more »